Our company has received notification from the patent firm that the Korean Patent Certificate for “Composition for Upper Respiratory Tract Drug Delivery and Its Administration Method” has been granted, under Application No. 10-2022-0140542.
The composition and administration method for upper respiratory tract drug delivery (OBM-B01), developed by Original BiomMdicals, has received notification from the Taiwan Food and Drug Administration (TFDA) approving the initiation of Phase I human clinical trials.
Our company has received notification from the patent firm that the European Patent Certificate for “Composition for Upper Respiratory Tract Drug Delivery and Its Administration Method” has been granted, under Application EP22204330.9.
Our company has received notification from the Joint Institutional Review Board (IRB) of Taipei Medical University and its affiliated hospital that our application for the project titled “First-in-Human Study of Inhalation of a Fixed-Ratio Combination of Vitamin B12 (Hydroxocobalamin, OHCbl) and Iron Chelator (Deferoxamine Mesylate, DFO) Using a Drug Nebulizer in Healthy Adults” has been approved.
Our company’s OBM-B01 cyanide compound drug project has been entrusted to OP NANOPHARMA Co., Ltd. for the development and manufacturing of the lyophilized formulation.
Our company’s invention, “Chelated Composite Micelles with Antibacterial Activity Against Gram-Negative Bacteria and Their Applications,” has been granted a Patent Approval Certificate by the Intellectual Property Office, Ministry of Economic Affairs, R.O.C., under Application No. 113121334.
Our company has received notification from the patent firm that the Canadian Patent Certificate for “Composition for Upper Respiratory Tract Drug Delivery and Its Administration Method” has been granted, under Application No. 3,179,962.
Our company has obtained a Chinese invention patent for the “Composition and Method for Upper Respiratory Tract Drug Delivery.” Patent Certificate Number: 8016515.
Our company has received notification from the patent office that the patent certificate for "Composition for Upper Respiratory Tract Drug Delivery and Its Administration Method" has been granted in China, with application number 202211335382.4.
Our company has signed a contract with Company S, which focuses on the cross-strait medical aesthetics market. Through our nano-emulsion technology, we will assist Company S in developing a sustained-release vitamin C+E product. Subsequently, Original BioMedical will exclusively supply the core raw materials.
Original BioMedicals is a specialized technology platform company for innovative drug development and pharmaceutical development services, possessing strong research capabilities and a wealth of product resources. Xinbai Pharmaceutical is a subsidiary of China Resources Pharmaceutical Group, while Rongchang Pharmaceutical is a professional pharmaceutical distributor. Adhering to the principles of win-win cooperation and joint development, the three parties will leverage their respective strengt
Our company has obtained an Australian invention patent for the "Composition for Upper Respiratory Tract Drug Delivery and Its Administration Method," with certificate number 2022259787.
